CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Open Calls for Patient and Clinician Input

Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the Drug Reimbursement Review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Rybelsus (semaglutide)

Indications: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in combination with other medicinal products for the treatment of diabetes

Call For Patient Input: October 29, 2020

Patient Input Closed: December 17, 2020

Dupixent (dupilumab)

Indications: Indicated in adults and adolescents 12 years and older as an add-on maintenance treatment for moderate-to-severe asthma characterized by type 2 inflammation. Indicated as maintenance therapy to improve lung function. Indicated as maintenance therapy for oral corticosteroid-dependent asthma irrespective of type 2 inflammatory markers.

Call For Patient Input: October 29, 2020

Patient Input Closed: December 17, 2020

Reblozyl (luspatercept)

Indications: Reblozyl® (luspatercept for injection) is indicated for the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia

Call For Patient Input: October 29, 2020

Patient Input Closed: December 17, 2020

TBC (risdiplam)

Indications: Spinal muscular atrophy

Call For Patient Input: October 22, 2020

Patient Input Closed: December 10, 2020

Jorveza (budesonide)

Indications: Maintenance of Eosinophilic esophagitis in adults

Call For Patient Input: October 7, 2020

Patient Input Closed: November 26, 2020

Veltassa (patiromer)

Indications: Hyperkalemia, adults (chronic kidney disease)

Call For Patient Input: October 2, 2020

Patient Input Closed: November 23, 2020

Enspryng (satralizumab)

Indications: Neuromyelitis optica spectrum disorder

Call For Patient Input: September 23, 2020

Patient Input Closed: November 12, 2020